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Original Studies
Background: Probiotics are the most frequently prescribed treatment for chil-
dren hospitalized with diarrhea in Vietnam. We were uncertain of the benefits 
of probiotics for the treatment of acute watery diarrhea in Vietnamese children.
Methods: We conducted a double-blind, placebo-controlled, rand-
omized trial of children hospitalized with acute watery diarrhea in Viet-
nam. Children meeting the inclusion criteria (acute watery diarrhea) 
were randomized to receive either 2 daily oral doses of 2 × 108 CFUs of 
a local probiotic containing Lactobacillus acidophilus or placebo for 5 
days as an adjunct to standard of care. The primary end point was time 
from the first dose of study medication to the start of the first 24-hour 
period without diarrhea. Secondary outcomes included the total duration 
of diarrhea and hospitalization, daily stool frequency, treatment failure, 
daily fecal concentrations of rotavirus and norovirus, and Lactobacillus 
colonization.
Results: One hundred and fifty children were randomized into each study 
group. The median time from the first dose of study medication to the start 
of the first 24-hour diarrhea-free period was 43 hours (interquartile range, 
15–66 hours) in the placebo group and 35 hours (interquartile range, 20–68 
hours) in the probiotic group (acceleration factor 1.09 [95% confidence 
interval, 0.78–1.51]; P = 0.62). There was also no evidence that probiotic 
treatment was efficacious in any of the predefined subgroups nor signifi-
cantly associated with any secondary end point.
Conclusions: This was a large double-blind, placebo-controlled trial in 
which the probiotic underwent longitudinal quality control. We found under 
these conditions that L. acidophilus was not beneficial in treating children 
with acute watery diarrhea.
Key Words: diarrhea, lactobacillus, norovirus, probiotic, randomized 
 controlled trial, rotavirus, Vietnam
(Pediatr Infect Dis J 2018;37:35–42)
Diarrheal diseases are a major global health issue, with the vast majority of the disease burden arising in young children 
residing in low-middle income countries.1 It was estimated that >7 
million children under the age of 5 years died in 2010; 15% of 
these deaths were attributable to diarrhea.2,3 Typically, episodes of 
diarrhea are self-limiting, and patients often recover without ever 
obtaining a diagnosis identifying the etiologic agent. In those who 
are diagnosed, rotavirus is the most frequently identified pathogen 
in young children, followed by an array of other viral, parasitic 
and bacterial agents.4 Vietnam is a rapidly developing low-middle 
income countries in Southeast Asia, with an estimated mortality rate 
of 23/1000 in children less than 5 years of age.3 The total number 
of deaths in this age bracket in Vietnam in 2010 was 34,940, 11% 
of which were associated with diarrhea.3 Oral rehydration solution, 
zinc, probiotics (in a multitude of formulations), and antimicrobials 
are the most commonly used treatments for children hospitalized 
with acute diarrhea in Vietnam, largely following WHO guidelines 
(with the exception of probiotics).5 The use of probiotics in Viet-
nam is common in both hospitals and the community,6 and we have 
previously estimated that >70% of 1500 children hospitalized with 
diarrhea in Ho Chi Minh City were prescribed a probiotic.7
In a Cochrane review of the effect of probiotics for the treat-
ment of acute watery diarrhea, Allen et al8 combined data from 
8014 participants who were enrolled in 63 studies. The authors 
noted extensive heterogeneity in study design, definitions, infect-
ing agents, probiotic organisms and dosages. Notwithstanding these 
caveats, a combined meta-analysis found probiotics to be effective 
in reducing the duration of diarrhea by a mean of 24.8 hours (95% 
confidence interval [95% CI], 15.9–33.6 hours), reduced the fre-
quency of stools on the second day of treatment by a mean of 1.8 
stools (95% CI, 0.45–1.14) and lowered the risk of developing per-
sistent diarrhea by 59% (95% CI for risk, 0.32–0.53). The authors 
advocated larger, more robust trial designs specifically focusing on 
pathogen identification and the incorporation of standard definitions 
and end points to accurately inform clinical guidelines. There is cur-
rently no international regulatory agreement for the manufacture 
or clinical use of probiotics,9,10 and additional scientific evidence is 
required to substantiate any potential health benefits of probiotics.11
We were uncertain as to the benefits of probiotics for the treat-
ment of children with acute watery diarrhea in Vietnam. Therefore, we 
sought to address many of the limitations raised in the Cochrane review 
by conducting a double-blind, randomized, placebo-controlled trial. 
Specifically, we aimed to test the hypothesis that 5 days of 2 oral daily 
doses of 2 × 108 CFUs of Lactobacillus acidophilus (L. acidophilus), 
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a regime used in diarrheal therapy in hospitals in Vietnam, would be 
superior to placebo in reducing the time from the first dose of study 
medication to the start of the first 24-hour period without diarrhea.12
MATERIALS AND METHODS
Study Population and Setting
We conducted a double-blind, randomized, placebo-controlled 
trial recruiting participants with acute watery diarrhea at Children’s 
Hospital 2 in Ho Chi Minh City, Vietnam. This 1400-bed hospital 
serves the local community and acts as tertiary referral center for chil-
dren with severe infectious diseases and noncommunicable diseases 
in southern Vietnam. A full description of the methods has been pub-
lished in the study protocol previously.12 Briefly, children (between 9 
and 60 months of age) hospitalized with acute watery diarrhea were 
screened for entry into the trial by study staff who had been appro-
priately trained in the trial procedures and had received good clinical 
practice (GCP) certification. Acute watery diarrhea was defined as the 
passage of loose or watery stools (taking the shape of the container) 
at least three times in a 24-hour period that did not contain blood 
or mucus with a history of less than 3 days. These inclusion crite-
ria are comparable to those defined in the Cochran review,8 “infants 
and children with 3 watery stools/day without visible blood or mucus 
(duration not stated)”. The reason for targeting these patients was to 
(1) avoid children who may progress to more severe disease mani-
festations, (2) avoid recruiting children who would receive empirical 
standard-of-care antimicrobial on admission to hospital, (3) quantify 
probiotics are standard of care for this presentation in this location, 
and (4) to quantify viral loads in those infected with either norovirus 
and rotavirus, of which acute watery diarrhea is the most common 
presentation of these infections. Patients were excluded if (1) they had 
at least one episode of diarrhea in the month before admission, (2) 
they were known to have short bowel syndrome or chronic (inflamma-
tory) gastrointestinal disease, (3) they were immunocompromised or 
immunosuppressed, (4) they were on prolonged steroid therapy, (5) or 
they were diagnosed as being severely dehydrated, to avoid recruiting 
those with a more severe manifestation of diarrhea.
A medical monitor oversaw the safety of the trial. Written 
informed consent to participate in the study was required from a 
parent or an adult guardian of all patients. The study protocol was 
reviewed and approved by the Ethical Committee of Children’s 
Hospital 2 and the Oxford Tropical Research Ethics Committee 
(OxTREC) of the United Kingdom. The trial was registered at Clini-
cal Trial.gov, number SRCTN88101063. Consort checklist provided 
in Supplemental Digital Content 5, http://links.lww.com/INF/C803.
Study Treatments and Quality Control
All patients received the standard of care according to the 
National Guidelines for the management of infectious diarrheal dis-
eases in children, which included oral rehydration solution and zinc, 
but typically not antimicrobials for acute watery diarrhea. However, 
participants were not excluded when prescribed antimicrobials, and 
all therapies were recorded in a standardized case report form (CRF). 
Participants received either 2 sachets of 1 × 108 CFUs of L. acidophi-
lus twice daily (ie, 4 × 108/day) or 2 sachets of identical tasting placebo 
(maltodextrin excipient only) dissolved in 10 mL of water. The study 
medications were purchased from, and manufactured by, Imexpharm 
pharmaceutical company (Cao Lanh, Vietnam) according to good 
manufacturing practices-World Health Organization (GMP-WHO) 
regulations; the appearance of the probiotic and placebo sachets and 
their contents were indistinguishable. The treatment regimens were 
identical in both groups: doses every 12 hours for 5 days. An addi-
tional dose was given (up to 2 extra doses in 4 hours) to participants 
who vomited within 30 minutes of taking the study medication.
For quality control purposes, we performed bacterial culture 
(for enumeration and identification) on a random selection of sachets 
(n=5) containing placebo and probiotic before the study initiation 
and at 3-monthly intervals (5 occasions in total). At all time points, 
the probiotic sachets contained >1 × 108 CFUs of L. acidophilus only 
(the specified contents of the sachet); all placebo sachets were ster-
ile. To determine the identity of the L. acidophilus in the sachets, we 
performed whole genome sequencing on the contents of the sachets. 
Genomic DNA was extracted using the Wizard Genomic DNA Puri-
fication Kit (Promega, WI), and 2 μg of genomic DNA was subjected 
to whole genome sequencing on an Illumina MiSeq 2500platform, 
following the manufacturer’s recommendations to generate 300 bp 
paired-end reads, as previously described.13 A de novo assembly was 
created using SPAdes v·3.7.1 using the “careful” option to optimize 
error correction; the genome sequence was submitted to Genbank 
under the accession number SRR4240524. An additional 12 complete 
L. acidophilus genome sequences were retrieved from public database 
and were aligned together with the aforementioned assembly using 
Mauve. Locally collinear blocks were trimmed and concatenated, and 
invariant sites and gaps were removed to produce a 1292-bp single 
nucleotide polymorphism (SNP) alignment. A maximum likelihood 
phylogeny was inferred from this alignment using PhyML with 100 
bootstrap replicates under the GTR substitution model. By phyloge-
netic analysis, the strain was confirmed to be L. acidophilus La-14 
and closely related to a previously sequenced strain (Supplemental 
Digital Content 1, http://links.lww.com/INF/C799).14 Reads were also 
mapped to the reference sequence of L. acidophilus La-14 (accession 
number NC_021181) using SMALT (version 0.7.4). Candidate SNPs 
were called against the reference sequence using SAMtools, and low-
quality SNPs were filtered based on these criteria: consensus quality 
<50, mapping quality <30, ratio of SNPs to reads at a position <75%, 
read depth <4, strand bias <0.001, mapping bias <0.001 or tail bias 
<0.001. As a result, 4 consensus SNPs and 1 intergenic deletion (2 bp) 
were identified in the L. acidophilus strain used in this study compared 
with the reference, indicating low genetic divergence between the 2.
Randomization, Concealment of Allocation and 
Blinding
Patients were randomly assigned to receive oral L. acidophi-
lus (probiotic) or placebo (1:1) according to a computer-generated 
randomization list using block randomization with variable blocks 
of length 4 and 6. A study pharmacist prepared visually matched 
sachets in identical, sequentially numbered treatment packs accord-
ing to the randomization list for dispensation in sequential order as 
participants were recruited. All participants, enrolling physicians 
and investigators were blinded to the treatment allocations. Attend-
ing physicians were responsible for enrolling the participants and 
ensuring that the study medications were given from the appropri-
ate treatment pack. Daily monitoring of all enrolled inpatients by 
one of the investigators ensured the uniform management and accu-
rate recording of clinical data in individual study notes.
Investigations and Follow-Up
Routine hematology and biochemistry tests were performed 
on admission to evaluate the severity of dehydration and disease. 
Multiplex real-time polymerase chain reaction (PCR) were per-
formed on all fecal samples collected on admission to detect Shi-
gella, Salmonella, Campylobacter coli and Campylobacter jejuni.15 
Additionally, quantitative real-time PCR was performed on the daily 
and follow-up fecal samples to diagnose norovirus and rotavirus 
and to calculate their viral loads.16 Furthermore, fecal samples taken 
on admission, on discharge or on the last day of follow up (1 or 2 
days after finishing the treatment course) and at outpatient follow-
up visits (7 or 8 days after finishing the treatment course for those 
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children whose parent/guardians agreed to return) were subjected 
to metagenomic DNA extraction and PCR-amplified to quantify the 
concentration of L. acidophilus (target copies/mL of feces).17,18
Clinical Outcomes
Patients were assessed twice daily until discharge for clini-
cal progress, diarrhea, vomiting, study medication compliance and 
adverse events, and the study staff collected daily fecal samples. On 
discharge and at follow-up, assessments were performed and fecal 
samples were collected.
The primary outcome was the time from the first dose of 
study medication to the start of the first 24-hour period without diar-
rhea as assessed by the treating physician or the participant’s parent/
guardian. Secondary end points included the total duration of diar-
rhea, the total duration of hospitalization, stool frequency in the first 
3 days after enrollment, treatment failure (defined as no resolution 
of diarrhea during the 5-day treatment course, severe symptoms for 
which treatment was stopped, the requirement for additional anti-
diarrheal treatments), the daily rotavirus and norovirus viral loads 
in patients with a PCR amplification–positive fecal samples and all 
adverse events. Additional exploratory end-points were the recur-
rence of diarrhea (defined as a new diarrhea episode since the initial 
episode as assessed at the day 14(+3) follow-up visit) and the vomit-
ing frequency in the first 3 days after enrollment.
Statistical Analysis and Sample Size Calculation
Data from Children’s Hospital 2 identified a median (inter-
quartile range) duration of hospitalization of 5 (3–6) days (mean and 
SD of log
10
-duration of 0.61 and 0.27) in our target population7 and 
an approximate normal distribution of the log-transformed data. As we 
had limited pre-existing data on overall length of diarrheal illness (pre-
hospitalized and hospitalized) and as children are usually discharged 
at the time of resolution of diarrhea, we used variability of the length 
of hospitalization as the basis of the sample size calculation. The trial 
was designed with the hypothesis that L. acidophilus was superior to 
placebo for acute watery diarrhea and was powered to detect a rela-
tive 20% decrease in the duration of diarrhea (measured in hours) of 
4 × 10≥8 CFUs of probiotics compared with placebo, corresponding to 
an absolute effect size of approximately 24 hours.8 For 80% power at the 
2-sided 5% significance level, a total of 123 participants per arm were 
required. To account for potential inadequacies in assumptions and 
some loss to follow-up, the sample size was increased by 22%. Thus, 
a total sample size of 300 participants, 150 in each arm, was recruited.
All statistical analyses were predefined in a detailed sta-
tistical analysis plan, which was finalized before the trial was 
unblinded (Supplemental Digital Content 6, http://links.lww.com/
INF/C804). All randomized participants were included in the main 
analysis population following the intention-to-treat principle. The 
primary outcome, the time from the first dose of study medication 
to the start of the first 24-hour diarrhea-free period, was compared 
between the study groups based on a lognormal accelerated failure 
time regression model. Children withdrawn or lost to follow-up 
before cessation of diarrhea were treated as right-censored at the 
time of withdrawal or loss to follow-up. Homogeneity of the treat-
ment effect was assessed in predefined subgroups.
The secondary and exploratory outcomes were compared 
between the treatment groups based on logistic regression for binary 
data (treatment failure and recurrence of diarrhea), quasi-Poisson 
regression for count data (stool frequency and vomiting frequency) 
and the lognormal accelerated failure time model for time-to-event 
data (total duration of diarrhea and duration of hospitalization), with 
treatment as the only covariate. Viral load measurements were sum-
marized by the area under the curve (AUC) of log
10
-transformed 
viral load measurements between enrollment (day 1) and day 7 and 





-transformed L. acidophilus 
bacteria load changes between enrollment and days 7 and 14, respec-
tively, were compared in the same way. All analyses were performed 
using the statistical software R version 3.1.1.19
RESULTS
Baseline Characteristics and Patient Recruitment
Between October 2014 and September 2015, 303 patients 
with acute watery diarrhea were screened for enrollment into this 
trial (Fig. 1). Three hundred of these patients (150 in each study 
FIGURE 1. Consort flow 
diagram for trial screening and 
randomization.
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arm) met the inclusion criteria and were randomly assigned to 
receive a best-selling Vietnamese brand of probiotic consisting of 
L. acidophilus only or placebo. Over 14 days of study follow-up, 
2 patients in the placebo arm and 3 patients in the probiotic arm 
withdrew from the study after receiving a maximum of 6 doses 
of study drug. One additional subject in the placebo arm received 
only 6 doses of study drug, and 1 patient in the probiotic group was 
lost to follow-up. The parents/guardians of 3 children randomized 
to the probiotic group gave alternative probiotics in addition to the 
study treatment, leaving 290 (147 in the placebo arm and 143 in the 
probiotic arm) in the per-protocol population. In total, 5 subjects in 
each arm received less than the scheduled 10 doses of study treat-
ment.
The demographic and baseline characteristics of patients 
were balanced between the 2 treatment groups in the intention to 
treat population (Table 1). The median age of the children was 16 
months, and approximately one third were female. The inclusion 
criteria made it more likely that we would enroll those with a viral 
infection than a bacterial infection, and this was the case as 56/150 
(37%) and 64/150 (43%) of the fecal samples were PCR amplifica-
tion positive for rotavirus and 38/150 (25%) and 30/150 (20%) of 
the fecal samples were PCR amplification positive for norovirus in 
the placebo arm and probiotic arm, respectively. The proportion of 
bacterial infections (for the pathogens screened by PCR amplifi-
cation: Salmonella, Campylobacter, and Shigella) was also com-
parable between the 2 groups. Finally, hematology or biochemical 
parameters were similar in both groups.
Primary Outcome and Subgroup Analyses
In the intention to treat population, the median time from 
the first dose of study medication to the start of the first 24-hour 
diarrhea-free period was 43 hours (interquartile range [IQR], 15–
66 hours) and 35 hours (IQR, 20–68 hours) in the placebo and the 
probiotic group, respectively. Despite an 8-hour difference between 
the median times to cessation of diarrhea, the overall distribution 
of the primary end point was similar in both groups, and a statisti-
cal comparison did not reach significance (P = 0.62; Table 2 and 
Fig. 2). There was also no evidence for probiotic efficacy in the per-
protocol population or in any of the predefined subgroups accord-
ing to age, prior treatment or pathogen (Table 2).
Secondary Outcomes and Adverse Events
Analyses of the secondary end points are shown in Table 3. 
There were no significant differences in the secondary outcomes 
or exploratory outcomes between the probiotic group and the pla-
cebo group. Specifically, the median total duration of diarrhea was 
TABLE 1. Baseline Characteristics by Treatment Group in the Intention to Treat 
Population
Characteristic Placebo (N=150) Probiotic (N=150)
Demographics, history and clinical examination
  Age (months), median (IQR) 15.5 (12.5–21.5) 15.6 (11.8–21.3)
  Sex (female) 49/150 (33%) 52/150 (35%)
  Weight (kg), median (IQR) 11.1 (9.0–12.0) 11.2 (9.0–12.0)
  Temperature (°C), median (IQR) 37.8 (37.1–38.3) 37.8 (37.2–38.5)
  Pulse (beats/min), median (IQR) 121.0 (121.0–128.0) 124.0 (121.0–128.0)
  Duration of diarrhea before enrollment (hours), median (IQR) 33 (20–53) 36 (24–51)
  Prior treatment with antibiotics in the previous month
   Yes 47/150 (31%) 38/150 (25%)
   No 90/150 (60%) 100/150 (67%)
   Unknown 13/150 (9%) 12/150 (8%)
  Prior treatment with probiotic in the previous week
   Yes 75/150 (50%) 82/150 (55%)
   No 59/150 (39%) 52/150 (35%)
  Unknown 16/150 (11%) 16/150 (11%)
Microbiology
  Rotavirus* 56/150 (37%) 64/150 (43%)
  Norovirus† 38/150 (25%) 30/150 (20%)
  Campylobacter 18/150 (12%) 11/150 (7%)
   C. Coli 3/18 (17%) 0/11 (0%)
   C. jejuni 15/18 (83%) 11/11 (100%)
  Shigella 20/150 (13%) 17/150 (11%)
  Salmonella 21/150 (14%) 14/150 (9%)
Hematology and biochemistry
  Hematocrit (%), median (IQR) 38.8 (36.5–41.6) 38.5 (36.4–41.2)
  White blood cell (K/μL), median (IQR) 11.1 (8.0–12.8) 11.3 (8.0–12.2)
Neutrophils (%), median (IQR) 53.6 (41.2–67.7) 51.8 (34.7–68.4)
Lymphocytes (%), median (IQR) 34.1 (22.5–46.9) 37.0 (23.3–53.5)
Eosinophils (%), median (IQR) 1.2 (1.0–1.7) 1.3 (1.0–1.9)
Platelet (K/μL), median (IQR) 317.9 (255.4–386.3) 322.0 (273.6–389.8)
Sodium (Na+) (mEq/L), median (IQR) 133.0 (131.0–136.0) 134.0 (131.0–135.0)
Potassium (K+) (mEq/L), median (IQR) 3.8 (3.5–4.1) 3.8 (3.5–4.1)
Urea (g/L), median (IQR) 1.3 (1.2–1.4) 1.3 (1.2–1.4)
Creatinine (mg/L), median (IQR) 4.4 (4.0–5.1) 4.6 (4.2–5.0)
*Placebo arm included 41 rotavirus monoinfections, 2 rotavirus and norovirus co-infections, 12 rotavirus and bacterial co-infections 
and 1 rotavirus and norovirus and bacterial co-infections. Probiotic arm included 52 rotavirus monoinfections, 1 rotavirus and norovirus 
co-infection, 10 rotavirus and bacterial co-infections and 1 rotavirus and norovirus and bacterial co-infection.
†Placebo arm included 25 norovirus monoinfections, 2 rotavirus and norovirus co-infections, 10 norovirus and bacterial co-infections 
and 1 rotavirus and norovirus and bacterial co-infection. Probiotic arm included 22 norovirus monoinfections, 1 rotavirus and norovirus 
co-infection, 6 norovirus and bacterial co-infections and 1 rotavirus and norovirus and bacterial co-infection.
IQR indicates interquartile range.
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identical at 76 hours (Supplemental Digital Content 2, http://links.
lww.com/INF/C800), and the median duration of the hospitalization 
was 78 hours (IQR, 53–104 hours) and 79 hours (IQR, 54–104 hours) 
in the placebo and the probiotic group, respectively (Table 3). Treat-
ment failure occurred in only 11 individuals in the placebo group and 
10 in the probiotic group. There was no difference in the number of 
episodes of diarrhea or vomiting between treatment arms, and recur-
rence of diarrhea occurred in 12% of subjects in each group.
To assess if there was any potential effect of L. acidophilus 
on those with a viral infection, we performed quantitative real-time 
PCR on longitudinal fecal samples from those infected with rota-
virus and norovirus (Fig. 3; Supplemental Digital Content 3, http://
links.lww.com/INF/C801). There was a substantial reduction in the 
number of target copies of rotavirus and norovirus over the 14-day 
follow-up period; the AUC of the viral loads were calculated to 
assess these dynamics between the 2 study arms. We found that the 
median AUC of rotavirus load (log
10
 copies/mL × days) was 63.25 
and 63.16 in the placebo and the probiotic group, respectively. The 
median AUC of norovirus loads (log
10
 copies/mL × days) were 
43.66 and 45.98 in the corresponding groups (Table 3). Finally, 
we measured the dynamics of L. acidophilus colonization over the 
course of the study follow up. L. acidophilus colonization was not 
distinct between the 2 groups, log
10
-transformed L. acidophilus 
load change in target copies after 7 and 14 days in both arms were 
−1.17 and −1.12 (log
10
 copies/mL) and 1.06 and −1.13 (log
10
 cop-
ies/mL) in the placebo and the probiotic group, respectively (Sup-
plemental Digital Content 4, http://links.lww.com/INF/C802). No 
adverse events were reported in either of the study groups.
DISCUSSION
The use of probiotics for treating acute diarrhea is conten-
tious, with various studies showing both positive and nonpositive 
effects. However, as highlighted in a Cochrane review, the study 
designs, selected probiotics and the target populations in the sci-
entific literature are inconstant, thus, leading to extensive vari-
ability in the combined data.8 We aimed to address many limita-
tions of poor study design in this trial. First, the study was double 
blinded and placebo controlled using a locally sourced probiotic, 
a brand that is commonly used in hospitals in Vietnam to treat 
diarrhea. Second, we assessed the quality of the probiotic by reg-
ular quantitative counts and via genome sequencing to identify 
TABLE 2. Summary of the Primary Outcome in All Patients and in Predefined Subgroups
Subgroup









Factor (95% CI);  
P Value
Test for Effect  
Heterogeneity  
(P Value)
All patients (intention-to-treat) 150 43 (15–66) 150 35 (20–68) 1.09 (0.78–1.51); P = 0.62  
Per-protocol population 147 43 (15–66) 143 33 (20–68) 1.09 (0.79–1.52); P = 0.60  
Age      0.2
  0–12 (months) 32 56 (27–91) 40 43 (18–85) 0.76 (0.40–1.46); P = 0.41  
  13–24 (months) 85 43 (6–70) 77 34 (21–68) 1.18 (0.75–1.87); P = 0.47  
  25–36 (months) 22 42 (22–56) 21 28 (14–53) 0.75 (0.33–1.73); P = 0.50  
  37–60 (months) 11 21 (1–30) 12 22 (21–62) 2.94 (0.96–8.95); P = 0.058  
Prior treatment with antibiotics in the past month      0.42
  Yes 47 48 (23–95) 38 45 (22–66) 1.34 (0.78–2.29); P = 0.29  
  No 90 42 (15–61) 100 28 (14–68) 0.96 (0.63–1.45); P = 0.83  
  Unknown 13 22 (3–41) 12 49 (12–70) 1.95 (0.47–8.07); P = 0.36  
Prior treatment with probiotics in the past week      0.47
  Yes 75 45 (19–70) 82 28 (17–62) 0.90 (0.59–1.37); P = 0.63  
  No 59 47 (12–68) 52 45 (22–78) 1.29 (0.73–2.29); P = 0.39  
  Unknown 16 24 (6–42) 16 54 (4–125) 1.56 (0.50–4.90); P = 0.44  
Pathogen      0.17
  Rotavirus 56 48 (18–66) 64 45 (21–76) 1.07 (0.62–1.85); P = 0.81  
  Norovirus 35 24 (5–64) 28 42 (26–76) 2.1 (1.01–4.37); P = 0.047  
  Infected by other bacteria 24 45 (23–64) 18 24 (20–64) 0.74 (0.34–1.61); P = 0.44  
  Unknown 35 46 (19–86) 40 27 (17–45) 0.78 (0.42–1.46); P = 0.43  
N refers to the number of subjects in each subgroup. Median and interquartile range (IQR) of the primary outcome were calculated for each randomized treat-
ment group separately using Kaplan–Meier estimation. Comparisons between groups were based on a parametric lognormal accelerated failure time regression 
models, with treatment as the only covariate. The acceleration factor refers to the estimated relative difference between the duration in the two arms. Values <1 refer 
to a faster estimated diarrhea clearance in the probiotics arm. Heterogeneity was tested with a likelihood ratio test for an interaction between treatment and each 
subgrouping variable.
CI indicates confidence interval.
FIGURE 2. Kaplan–Meier curve of the primary outcome 
by treatment group. Curves showing the probability of still 
having diarrhea, that is, the probability of not yet having 
reached the onset of the first 24-hour diarrhea-free period 
(y axis), against the time since randomization (x axis) 
by treatment arm in the intention-to-treat population. 
Lactobacillus acidophilus (broken line) and placebo (solid line).
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the strain composing the probiotic. Third, we measured opposite 
end points on a robust sample size in an appropriate population. 
Finally, we aimed to stratify outcomes by etiologic agent and per-
formed quantitative PCR for norovirus, rotavirus and L. acido-
philus in the longitudinally collect fecal specimens. Therefore, 
we suggest that this study provides strong evidence for a lack of 
efficacy of L. acidophilus in treating children with acute watery 
diarrhea in Asia.
The use of probiotics in Vietnam is common, and they are 
considered to be safe and cheap; one sachet of the probiotic used 
in this study cost approximately 1500 Vietnam Dong (<0.10 USD), 
and they are frequently prescribed in hospitals and in the commu-
nity for diarrhea. Here, the duration of acute diarrhea (time from 
the first dose of study medication to the start of the first 24-hour 
period without diarrhea or total duration of diarrhea) was not sta-
tistically different between children who received L. acidophilus 
or placebo, and there was no evidence that this probiotic provided 
benefit in the overall population or in any of the predefined sub-
groups. Furthermore, we observed no difference in norovirus or 
rotavirus viral loads between the two groups. The same observation 
was true for colonization with L. acidophilus, suggesting that oral 
L. acidophilus may even not efficiently colonize the gastrointestinal 
tract during acute diarrhea.
L. acidophilus La-14 is a common probiotic that has been 
used in various studies previously20,21 and has been show to boost 
immunoglobulin G responses during oral cholera immunization.21 
Furthermore, this strain has been found to intrinsically resistant 
to an array of antimicrobials and to produce a bacteriocin with 
antimicrobial activity against Listeria moncytogenes.22 There are 
no previous studies specifically assessing the potential use of L. 
acidophilus La-14 as a treatment for acute diarrhea, and strain 
selection may be pivotal. There is some scientific evidence that 
L. acidophilus may have an inhibitory effect on gastrointestinal 
pathogens; a recent laboratory study conducted in Korea assessed 
the antiviral activity of probiotics (including L. acidophilus) for 
rotavirus in vero cells.23 This study found that L. acidophilus had 
the second highest inhibitory effect after Bifidobacterium longum 
and significantly shortened the duration of diarrhea in a limited 
number of patients.23 Further, data generated using L. acidophi-
lus (strain NCFM) showed that strain selection was important 
in stimulating rotavirus-specific antibody and B cell responses 
in gnotobiotic pigs vaccinated with rotavirus vaccine. Our data 
suggest that further, more physiologic, investigations need to be 
performed to assess there is a potential mechanism for a clinical 
impact on diarrhea with L. acidophilus.
There is an urgent need for new therapies for diarrhea; 
extensive antimicrobial resistance in many Gram-negative 
enteric pathogens means that we are becoming short of alterna-
tive options.24 Probiotics offer an attractive solution and may 
have an effect if a functional formulation can be identified and 
TABLE 3. Summary of Secondary and Exploratory Outcomes
Outcome Placebo (N=150) Probiotic (N=150) Comparison Estimate (95% CI); P Value
Secondary outcomes
  Total duration of diarrhea   AF of time to diarrhea clearance
   Median (IQR) (hours) 76 (54–109) 76 (54–111) 1.02 (0.89–1.17); P = 0.75
  Treatment failure*   OR of treatment failure
   Frequency (%) 11/150 (7%) 10/150 (7%) 0.90 (0.36–2.21); P = 0.82
  Total stool frequency in the first 3 days   Relative difference in stool frequency
   Median (IQR) (count) 7 (3–15) 8 (3–15) 1.05 (0.83–1.32); P = 0.68
  Rotavirus viral load AUC N=42† N=52†  
   Median (IQR) (log10 copies/mL) 63.99 (57.98–68.87) 63.76 (58.59–67.37) Adjusted absolute mean difference
   Mean (log10 copies/mL) 63.25 63.16 −1.27 (−3.68–3.14); P = 0.87
  Norovirus viral load AUC N=25† N=22†  
   Median (IQR) (log10 copies/mL) 43.29 (39.02–49.82) 44.70 (41.31–51.03) Adjusted absolute mean difference
   Mean (log10 copies/mL) 43.66 45.98 2.63 (−1.58 to 6.85); P = 0.21
  Duration of hospitalization   AF of duration of hospitalization
   Median (IQR) (hours) 78 (53–104) 79 (54–104) 0.97 (0.85–1.11); P = 0.66
  L. acidophilus bacteria load change after 7 days (log10 
copies/mL)
N=37‡ N=51‡  
   Median (IQR) (log10 copies/mL) −1.17 (−1.63 to 1.15) 1.06 (−1.43 to 1.28) Adjusted absolute mean difference
   Mean (log10 copies/mL) −1.18 1.39 0.4 (−1.23 to 1.04); P = 0.21
  L. acidophilus bacteria load change after 14 days (log10 
copies/mL)
N=34‡ N=34‡  
   Median (IQR) (log10 copies/mL) −1.12 (−1.46 to 1.30) −1.13 (−1.03 to 1.09) Adjusted absolute mean difference
   Mean (log10 copies/mL) −1.12 −1.36 1.095 (−1.48 to 1.67); P = 0.75
Exploratory outcomes
  Recurrence of diarrhea   OR of recurrence of diarrhea
   Frequency (%) 18/150 (12.00%) 18/150 (12.00%) 1.00 (0.50–2.02); P = 1.00
  Total vomiting frequency in the first 3 days   Relative difference in vomiting 
frequency
   Median (IQR) (count) 1 (0–5) 1 (0–5) 1.21 (0.80–1.82); P = 0.37
Comparisons were based on lognormal accelerated failure time models (total duration of diarrhea, duration of hospitalization), logistic regression (treatment failure, recurrence 
of diarrhea), quasi-Poisson regression (stool and vomiting frequency) and linear regression with adjustment for baseline log10-viral load or log10-bacterial load (norovirus and rotavirus 
AUC, Lactobacillus acidophilus bacteria load change after 7 days and 14 days). Median (IQR) of total duration of diarrhea and duration of hospitalization were computed based on 
Kaplan–Meier estimation.
*Treatment failure events were no resolution of diarrhea after 5 days of treatment (7 patients on placebo, 5 on probiotics), requirement for additional antidiarrheal treatment (3 
on placebo, 2 on probiotics), or both of these reasons (1 on placebo, 3 on probiotics).
†Longitudinal viral load measurements were only performed in patients without bacterial co-infection (Placebo: 40 rotavirus, 23 norovirus, 2 rotavirus and norovirus; Probiotic: 
51 rotavirus, 21 norovirus, 1 rotavirus and norovirus). AUCs could not be computed for 1 patient with rotavirus infection, 1 patient with rotavirus and 3 patients with norovirus 
withdrew at day 1.
‡Longitudinal L. acidophilus bacteria load measurements were only available for patients who agreed to follow-up after discharge (Placebo: 37 after 7 days, 34 after 14 days; 
Probiotic: 51 after 7 days, 34 after 14 days).
AF indicates acceleration factor; AUC, area under the curve of log10-transformed viral load from day 1 to 7; CI, confidence interval; IQR, interquartile range; OR, odds ratio.
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studies are suitably powered. Pooled data from 4 small RCTs 
from France, Ecuador, Peru and Thailand found a reduction in 
mean duration of diarrhea caused by predominantly unknown 
pathogens in children treated with heat-killed L. acidophi-
lus LB.25 While, similar to our data, a group in India found 
no difference in the duration of diarrhea, stool frequency and 
the duration of hospitalization with tyndalized L. acidophilus 
(undefined strain) in acute diarrhea study in young children.26 
Overall, published meta-analyses suggest that diarrheal epi-
sodes are shortened by approximately 24 hours with Lacto-
bacillus rhamnosus GG (LGG), L. acidophilus, L. bulgaricus 
and L. reuteri.27,28 These findings have led to various guidelines 
regarding the rational clinical use of probiotics in pediatric 
acute diarrhea diseases.29,30 Our data question the conclusion 
of these findings and suggest that L. acidophilus may not ben-
eficial for treating acute diarrhea in children in a low-middle 
income country.
Our study has limitations, which need to be considered in the 
context of the presented data. First, the time to cessation of symp-
toms was assessed by a caregiver or a patient/guardian and may vary 
according to those recording these data. Second, we were unable to 
accurately assess the type and duration of antimicrobial given to chil-
dren before inclusion in this study, which may affect duration and type 
of symptoms. Notwithstanding these limitations, we performed an 
adequately powered, double-blind, study under operational conditions 
with a common available and routinely used probiotic.
In conclusion, we found that L. acidophilus did not reduce 
the time from the first dose of study medication to the start of the 
first 24-hour period without diarrhea in comparison to placebo. 
Further, there was no difference between intervention and placebo 
in the total duration of diarrhea, the total duration of hospitaliza-
tion, stool frequency during the first 3 days of treatment, treatment 
failure or daily rotavirus and norovirus fecal loads. Our data add 
additional evidence regarding the role of probiotics in treating diar-
rheal disease and suggest that L. acidophilus may not have a meas-
urable effect in this setting.
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